in the Parkinson's model created with 6-OHDA, the application is performed unilaterally intrastriatically. after tretment, should the dopamine level be measured through the striatum on the side where the lesion occurs? or how should I decide which brain hemisphere to use for examining various parameters (oxidative stress and apoptosis)?
I would be glad if you help me.
Thank you very much in advance.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227396/
Please read this guide prepared by NIH concerning 6-OHDA model of parkinsonism...very helpful
Biomedicine figure in this guidr demonstrates how you would deal with 2 hemispheres...the figure shows how to devide each hemisphere as dorsal and ventral parts....then obtains 3 punches from each hemisphere to perform your lab measurements...please refere to figures of the guide of NIH
Hi Naile Merve Güven
While several studies of unilateral 6-OHDA injection in the medial forebrain bundle of mice analyze the contralateral side of the brain for motor and neuropathological features related to Parkinson's disease.
There are many other studies too that compare both the regions for neurotransmitter levels and neuropathological features.
Please find the protocol attached for unilateral injection and selection of the brain region.
Article Behavioral characterization of the 6-hydroxidopamine model o...
Thanks,
- Badges
- Science topic